There is no pharmacological reason one time is better than another in terms of drug efficacy
It's no wonder that, since this new class of appetite-curbing GLP-1 medications, including Ozempic, Wegovy, and Zepbound, burst into public consciousness, nearly $1 billion of venture capital dollars have been injected into the growing sector of weight-loss companies, which is now awash with startups prescribing the drugs, according to PitchBook data from the last year and a half
July 17, 2025: EU Clears Ozempic for Heart Conditions, Even Though Reports of Side Effects Are Rising Drug regulators in the European Union have given doctors the all-clear to prescribe Ozempic to treat peripheral artery disease, a type of heart condition
Am J Respir Crit Care Med 2013;187:572-5
This creates a practical paradox
However, a blood test is not a diagnosis